Prevention of cytomegalovirus disease in solid organ transplant patients: Prophylactic versus preemptive therapy

American Journal of Health-System Pharmacy

Volumn 63, Issue SUPPL. 5, 2006, Pages

  Baillie, G Mark ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Surgery/Critical Care Pharmacy Services   (United States)

Author keywords

Antivirals; Costs; Cytomegalovirus infections; Diagnosis; Economics; Protocols; Resistance; Tests, laboratory; Toxicity; Transplantation

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; PLACEBO; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH ECONOMICS; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; NEUTROPENIA; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

EID: 33749163089     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060378     Document Type: Conference Paper

References (21)

1. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997; 10:86-124.
2. Preiksaitis JK, Brennan DC, Fishman J et al. Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation final report. Am J Transplant. 2005; 5:218-27.
3. Singh N, Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis. 2001; 32:742-51.
4. McEvoy GK, ed. Foscarnet sodium. In: AHFS drug information 2006. Bethesda, MD: American Society of Health-System Pharmacists; 2006:845-50.
5. Vistide package insert. Foster City, CA: Gilead Sciences, Inc.; 2000 Sep.
6. Balfour HH Jr, Chace BA, Stapleton JT et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989; 320:1381-7.
7. Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet. 1997; 350:1729-33.
8. Paya C, Humar A, Dominguez E et al. Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4:611-20.
9. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998; 338:1741-51.
10. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999; 340:1462-70.
11. Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000; 356:645-9.
12. Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis. 2004; 189:1615-8.
13. Valcyte package insert. Nutley, NJ: Roche Laboratories Inc.; 2003 Sep.
14. Balfour HH Jr. Antiviral drugs. N Engl J Med. 1999; 340:1255-68.
15. Wiltshire H, Paya CV, Pescovitz MD et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005; 79:1477-83.
16. Singh N, Wannstedt C, Keyes L et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation. 2005; 79:85-90.
17. Anon. Cytomegalovirus. Am J Transplant. 2004; 4(suppl 10):51-8.
18. Singh N, Yu VL. Severing the Gordian knot of prevention of cytomegalovirus in liver transplant recipients: the principle is the sword, Liver Transpl. 2005; 11:891-4.
19. Singh N, Wannstedt C, Keyes L et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation. 2005; 79:1428-34.
20. Cytovene package insert. Nutley, NJ: Roche Laboratories Inc.; 2000 Sep.
21. McEvoy GK, ed. Valacyclovir hydrochloride. In: AHFS drug information 2006. Bethesda, MD: American Society of Health-System Pharmacists; 2006:840-3.